Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells.

Ah-Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin-Blank N, Fabre EE, Schischmanoff O.

J Cell Mol Med. 2016 Oct;20(10):1956-65. doi: 10.1111/jcmm.12887. Epub 2016 Jul 27.

2.

[Bilateral hypertrophy of Wharton duct revealing Sjögren syndrome].

Khammassi N, Souissi I.

Pan Afr Med J. 2015 Oct 21;22:170. doi: 10.11604/pamj.2015.22.170.8103. eCollection 2015. French. No abstract available.

3.

STAT3 inhibitors for cancer therapy: Have all roads been explored?

Fagard R, Metelev V, Souissi I, Baran-Marszak F.

JAKSTAT. 2013 Jan 1;2(1):e22882. doi: 10.4161/jkst.22882. Review.

4.

A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line.

Souissi I, Ladam P, Cognet JA, Le Coquil S, Varin-Blank N, Baran-Marszak F, Metelev V, Fagard R.

Mol Cancer. 2012 Mar 16;11:12. doi: 10.1186/1476-4598-11-12.

5.

A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB.

Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, Roger C, Dusanter-Fourt I, Varin-Blank N, Cao A, Metelev V, Baran-Marszak F, Fagard R.

BMC Cell Biol. 2011 Apr 12;12:14. doi: 10.1186/1471-2121-12-14.

Supplemental Content

Loading ...
Support Center